002317SZSE

Announcement on Subsidiary Obtaining Japanese Patent Certificate

Guangdong Zhongsheng Pharmaceutical Co.,Ltd.·June 22, 2026·2 pages

✨ AI Summary

Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Zhongsheng Ruichuang Biotechnology Co., Ltd., has obtained a patent certificate from the Japan Patent Office for the crystal form and preparation method of a ketone amide derivative. This patent is a core patent for the company's oral drug Leritrelvir (乐睿灵®), an anti-novel coronavirus drug. The patent is expected to enhance intellectual property protection and leverage the company's independent intellectual property advantages.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announcement on Subsidiary Obtaining Japanese Patent Certificate

The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations or material omissions.

Recently, Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a patent certificate issued by the Japan Patent Office for its subsidiary, Zhongsheng Ruichuang Biotechnology Co., Ltd. The details are as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.